【摘要】：目的本Meta分析的目的是評(píng)估依折麥布聯(lián)合他汀治療高膽固醇血癥(HC)的安全性。方法通過(guò)檢索Pubmed、Cochrane Library、EMBASE三個(gè)數(shù)據(jù)庫(kù)中從2002年1月至2015年10月收錄的文獻(xiàn),兩名研究者獨(dú)立篩選關(guān)于依折麥布聯(lián)合他汀治療HC的隨機(jī)對(duì)照試驗(yàn)(RCT)、提取數(shù)據(jù)、評(píng)估文獻(xiàn)質(zhì)量,采用固定效應(yīng)模型計(jì)算比值比(OR),并用Review Manager 5.2統(tǒng)計(jì)軟件進(jìn)行Meta分析并得出研究結(jié)論。結(jié)果共納入20篇RCT,包括14856個(gè)患者,依折麥布聯(lián)合他汀與單用他汀治療高膽固醇血癥相比:總的不良事件發(fā)生率無(wú)差別(OR=0.95;95%CI[0.85-1.0];P=0.34),治療退出發(fā)生率無(wú)差別(OR=1.15;95%CI[0.92-1.44];P=0.22),嚴(yán)重的不良事件發(fā)生率無(wú)差別(OR=1.04;95%CI[0.75-1.45];P=0.81),胃腸道不良事件發(fā)生率無(wú)差別(OR=1.26;95%CI[0.97-1.63];P=0.08),過(guò)敏事件發(fā)生率無(wú)差別(OR=0.74;95%CI[0.41-1.35];P=0.33),肌酸激酶(CK)升高10倍以上的發(fā)生率無(wú)差別(OR=1.07;95%CI[0.51-2.23];P=0.86),谷丙轉(zhuǎn)氨酶(ALT)升高3倍以上的發(fā)生率無(wú)差別(OR=1.01;95%CI[0.58-1.77];P=0.96),谷草轉(zhuǎn)氨酶(AST)升高3倍以上的發(fā)生率無(wú)差別(OR=1.21;95%CI[0.61-2.39];P=0.16),兩組不良事件發(fā)生率相似,無(wú)統(tǒng)計(jì)學(xué)差異。結(jié)論這篇Meta分析表明依折麥布與他汀聯(lián)用和單用他汀相比,不良事件發(fā)生率相似,兩組間無(wú)統(tǒng)計(jì)學(xué)差異。
[Abstract]:Objective the purpose of this Meta analysis was to evaluate the safety of etomab combined with statin in the treatment of hypercholesterolemia (HC). Methods by searching the literature collected from January 2002 to October 2015 in three Pubmed,Cochrane Library,EMBASE databases, the two researchers independently screened the (RCT), extraction data of the randomized controlled trial on the treatment of HC with efolib combined with statin. The literature quality was evaluated, the ratio (OR), was calculated by fixed effect model, and the Meta analysis was carried out with Review Manager 5.2 statistical software, and the research conclusions were drawn. Results A total of 20 articles of RCT, included 14856 patients. Compared with statins alone, there was no difference in the incidence of total adverse events (OR=0.95;95%CI [0.85 鈮，

本文編號(hào)：2493049